BVS Stock Analysis: Buy, Sell, or Hold?
BVS - Bioventus Inc. Class A Common Stock
$7.93
0.11 (1.41%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When BVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BVS shows positive signals but monitor for confirmation. Market pricing in 1.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BVS shows positive signals but monitor for confirmation. Market pricing in 1.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.37
Based on 12.3% avg growth
INTRINSIC VALUE TODAY
$8.30
4.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BVS is currently trading at $7.93, which is considered slightly high relative to its 30-day fair value range of $7.51 to $7.97. The stock's valuation (Forward PE: 9.8) is in line with its historical norms (9.5). At these levels, the market is pricing in 1.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $7.57, while resistance sits at $8.35.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+91.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $7.57, while resistance sits at $8.35.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+91.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$7.51 -
$7.97
Company Quality Score
60/100
(HOLD)
Options IV Signal
41th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
66.9%
All Signals
- NEUTRAL: Options fairly priced (IV 41th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 91.8% below Wall St target ($15.00)
- NEUTRAL: Market pricing in 1.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$7.51 -
$7.97
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.23
(15.6%)
Support & Resistance Levels
Support Level
$7.57
Resistance Level
$8.35
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
9.84
Wall Street Target
$15.00
(+91.8%)
Revenue Growth (YoY)
-0.2%
Profit Margin
1.8%
Valuation Premium vs History
+1.2% premium
PE vs Historical
9.8 vs 9.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.2%
(market-implied from PE analysis)
1-Year Target
$7.91
(+1%)
2-Year Target
$8.01
(+2%)
3-Year Target
$8.10
(+4%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
PE COMPRESSION
$7.83
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 20.5%)
$30.98
(+296%)
Base:
(SPY PE: 9.8, Growth: 20.5%)
$13.67
(+75%)
Bear:
(PE: 8.4, Growth: 20.5%)
$11.62
(+49%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (49x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 48.50 | Current EPS (TTM): $0.16
Bull Case
$17.07
(+115%)
Analyst growth 100.0%, PE expands to 53.4
Base Case
$15.52
(+96%)
Market implied 100.0%, PE stable at 48.5
Bear Case
$5.28
(-34%)
Severe decline -20.0%, PE contracts to 41.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 1:01 AM ET
Data refreshes hourly during market hours. Next update: 2:01 AM
Data refreshes hourly during market hours. Next update: 2:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$427 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced BVS Option Strategies
Professional options setups generated by AI based on today's BVS price and gamma walls.
